CBD oil study shows significant improvement in patients with treatment-resistant epilepsy

August 10, 2018, University of Alabama at Birmingham
Credit: CC0 Public Domain

Findings from the landmark study at the University of Alabama at Birmingham on cannabidiol, or CBD oil, provide the published evidence of significant improvements in seizure frequency and other measures of efficacy in patients with treatment-resistant epilepsy. Published in the journal Epilepsy and Behavior, the results indicate use of CBD oil reduced adverse events and seizure severity, in addition to a reduction in overall seizure frequency.

The published results focus on 132 patients, 72 children and 60 adults, with intractable epilepsy who did not respond to traditional therapies. The study was launched in 2015 following an act by the Alabama legislature—commonly called Carly's Law—that authorized the UAB Epilepsy Center and Children's of Alabama to conduct studies of cannabidiol, a component of cannabis.

The study analyzed data from the 132 patients at baseline and at visits at 12, 24 and 48 weeks. Seizure frequency decreased from a mean of 144 seizures every two weeks at baseline to 52 seizures over two weeks at 12 weeks into the study. The reduction remained stable through the 48-week study period.

"This is a highly significant reduction in the number of seizures that the majority of patients experienced, nearly a two-thirds reduction across the entire study population," said Martina Bebin, M.D., professor in the Department of Neurology in the School of Medicine and principal investigator of the pediatric arm of the study. "Some patients experienced an even greater reduction of ."

The research team also scored patients on an profile, or AEP score. For all participants, AEP decreased from 40.8 at the beginning of CBD therapy to 33.2 at the 12-week visit. The investigators also employed the Chalfont Seizure Severity Scale to assess overall severity of seizures. Scores decreased from 80.7 at baseline to 39.2 at 12 weeks. Scores for both measures remained stable at the 48-week mark.

"An improvement of 10 points or more on the CSS Scale is clinically significant," said Jerzy Szaflarski, M.D., Ph.D., director of the UAB Epilepsy Center and principal investigator of the adult arm of the study. "We saw improvements between baseline and 12-week visits in the 30- to 40-point range for each group, as much as a 50 to 60 percent improvement, indicating results that are not only statistically significant, but also highly clinically significant for the group as a whole."

The investigators also noted parallel decreases in both seizure severity and seizure frequency, indicating that, for many patients, use of CBD oil led to both fewer and less intense seizures.

The investigators point out that the oil used in the studies was a pharmaceutical-grade CBD oil produced by Greenwich Biosciences, known as Epidiolex. The purified oil contains only trace amounts of THC, the psychotropic component of cannabis.

Previous observational and randomized controlled studies have confirmed the safety and tolerability of Epidiolex, so the UAB team focused on analysis of the AEP data, which showed a significant decrease in the overall side effects reported by patients.

"Perhaps more importantly, the AEP scores remained stable throughout the study period despite further increases in CBD dosing and decreases in other anti-seizure medications," Szaflarski said. "Of note is that only two participants in the pediatric and two in the adult portions of the study withdrew because of adverse events alone."

"The results of this open-label safety study indicate significant improvements in seizure severity, adverse effects and frequency at 12 weeks, with response maintained over the 48-week duration of therapy," Bebin said. "The results are particularly interesting since, rather than enrolling patients with a specific diagnosis, we enrolled patients of all ages with various treatment-resistant epilepsies, indicating that CBD oil may be effective across the spectrum of epileptic conditions."

On June 25, the U.S. Food and Drug Administration approved Epidiolex for seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, marking the first FDA approval of a purified drug derived from cannabis. While this approval paves the way for patients with these rare conditions to receive CBD in the near future, it also provides all patients with epilepsy an additional efficacious and well-tolerated treatment option.

Explore further: Cannabidiol significantly reduces seizures in patients with severe form of epilepsy

Related Stories

Cannabidiol significantly reduces seizures in patients with severe form of epilepsy

May 17, 2018
Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a "high" and has been an increasing focus of medical research, was shown in a new large-scale, randomized, controlled trial to significantly ...

FDA approves epidiolex for severe forms of epilepsy

June 28, 2018
(HealthDay)—The U.S. Food and Drug Administration has approved Epidiolex (cannabidiol) oral solution for treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome for patients age 2 years and older.

Cannabis compound reduces seizures

February 27, 2018
About one third of patients treated for epilepsy continue to have seizures. Cannabidiol (CBD), one of the many active compounds in the cannabis (marijuana) plant, has gained attention as a treatment for epilepsy. Purified ...

Cannabis derivative cannabidiol reduces seizures in severe epilepsy disorder

May 24, 2017
After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol reduced seizure frequency by 39 percent for patients with Dravet syndrome - a rare, severe form of epilepsy - in the first large-scale ...

Cannabidiol efficacious for lennox-gastaut drop seizures

January 26, 2018
(HealthDay)—For patients with drop seizures associated with Lennox-Gastaut syndrome, add-on cannabidiol is associated with a reduction in monthly drop seizure frequency, according to a study published online Jan. 24 in ...

CBD oil may reduce frequency and severity of epileptic seizures

December 5, 2016
Cannabidiol oil, also known as CBD oil, reduces the frequency and severity of seizures in children and adults with severe, intractable epilepsy, according to findings presented by researchers from the University of Alabama ...

Recommended for you

Perinatal hypoxia associated with long-term cerebellar learning deficits and Purkinje cell misfiring

August 18, 2018
Oxygen deprivation associated with preterm birth leaves telltale signs on the brains of newborns in the form of alterations to cerebellar white matter at the cellular and the physiological levels. Now, an experimental model ...

People are more honest when using a foreign tongue, research finds

August 17, 2018
New UChicago-led research suggests that someone who speaks in a foreign language is probably more credible than the average native speaker.

Critical role of DHA on foetal brain development revealed

August 17, 2018
Duke-NUS researchers have found evidence that a natural form of Docosahexaenoic Acid (DHA) made by the liver called Lyso-Phosphatidyl-Choline (LPC-DHA), is critical for normal foetal and infant brain development, and that ...

Automated detection of focal epileptic seizures in a sentinel area of the human brain

August 17, 2018
Patients with focal epilepsy that does not respond to medications badly need alternative treatments.

Men and women show surprising differences in seeing motion

August 16, 2018
Researchers reporting in the journal Current Biology on August 16 have found an unexpected difference between men and women. On average, their studies show, men pick up on visual motion significantly faster than women do.

Brain response study upends thinking about why practice speeds up motor reaction times

August 16, 2018
Researchers in the Department of Physical Medicine and Rehabilitation at Johns Hopkins Medicine report that a computerized study of 36 healthy adult volunteers asked to repeat the same movement over and over became significantly ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym868752
not rated yet Aug 10, 2018
 I am a young man of 45 years now and was diagnosed with diabetes last summer. I was having lots of symptom like weak erection, weakness of the body, dry lips and palms, and even restlessness in the legs and shrinking of my general body build ups. My head was itching very much. I was seeking something to help regain my life to be able to do things for myself. Through my primary physician i learnt about a Diabetic disease herbal formula from NATURAL HERBAL GARDENS and their success rate with the treatment, i immediately started on the Diabetes disease herbal protocol, I am glad to report the herbal formula worked effectively and there was no side effects, I had a total decline in symptoms, the weak erection, restlessness and other symptoms stopped, my Diabetes disease is totally REVERSED, Here is a link to the website we ordered from ww w.naturalherbalgardens.c om This Herbal Protocol is Incredible!!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.